Webinar: Redefining Excellence in the Era of AI and Human Collaboration

Discover your potential savings with our ROI Calculator

Webinar: Elevating Customer Experience Through Quality

FDA 21 CFR Part 820 Compliance Software for Modern Medical Device Manufacturers

FDA 21 CFR Part 820 Compliance Software

FDA 21 CFR Part 820—commonly known as the Quality System Regulation (QSR)—outlines the framework that medical device manufacturers must follow to ensure safety, effectiveness, and quality. Compliance isn’t just a regulatory box to check—it’s mission-critical. Failure to comply can result in warning letters, product recalls, or even bans from the U.S. market.

Modern fda 21 cfr part 820 compliance software for medical devices helps manufacturers centralize quality processes, automate documentation, and ensure audit readiness while accelerating time-to-market. With increasing scrutiny from the FDA, digitizing compliance has become the only viable path forward.

Request an Online Demo
FDA 21 CFR Part 820 Compliance Software

What Is 21 CFR Part 820 Under FDA QMSR?

21 CFR Part 820 is the FDA's Quality Management System Regulation (QMSR), the federal regulation that establishes the quality system requirements medical device manufacturers must meet to legally market devices in the United States. The QMSR became effective on February 2, 2026, replacing the FDA's former Quality System Regulation (QSR) with a framework that incorporates ISO 13485:2016 directly by reference, rather than restating equivalent requirements in FDA's own language.

In practice, this means manufacturers must maintain quality processes and records that are controlled, traceable, and inspection-ready at all times, not assembled after the fact for an audit. The QMSR's scope touches nearly every function within a medical device organization, including design and development, production, supplier management, complaint handling, CAPA, internal audits, training, and management oversight. Software that can connect these areas into a single, evidence-generating system is quickly becoming the practical way manufacturers meet that expectation.

Understanding FDA 21 CFR Part 820: Core Requirements

Under the QMSR, 21 CFR Part 820 no longer stands as a self-contained set of FDA-written requirements across Subparts A through O. Instead, the regulation now incorporates ISO 13485:2016 by reference, for most quality system requirements, Part 820 points directly to the corresponding clause of ISO 13485:2016 rather than restating it.

This significantly streamlines the regulatory text itself, but it does not reduce what manufacturers must actually do: the substantive requirements for design controls, document control, production and process controls, corrective and preventive action, complaint handling, and supplier management remain in force, they now live primarily within ISO 13485:2016 rather than within FDA's own subparts.

Watch Demo Now
Understanding FDA 21 CFR Part 820: Core Requirements


What FDA-Specific Requirements Remain Under Part 820?

ISO 13485 forms the quality-management foundation of the current QMSR, but manufacturers still must comply with a set of FDA-specific requirements that ISO 13485 does not fully cover. These retained FDA-specific provisions span the following main areas:

  • Complaint handling and complaint records - FDA-specific documentation and handling expectations beyond what ISO 13485 requires.
  • Medical Device Reporting requirements - mandatory reporting of adverse events and malfunctions to the FDA.
  • Corrections and removals - FDA-specific obligations around field corrections and product removals.
  • Servicing records - recordkeeping requirements for post-sale device servicing.
  • Labeling and packaging controls - FDA-specific labeling and packaging requirements.
  • Unique Device Identification and traceability - UDI requirements tied to FDA's broader device identification framework.
  • Design and development controls - retained emphasis on design control documentation and traceability.
  • Production and process controls - controls over manufacturing processes and process validation.
  • Supplier and purchasing controls - evaluation and control of suppliers and purchased materials.
  • CAPA and nonconformance management - corrective and preventive action tied to nonconforming product.
  • Internal audits and management reviews - a notable change under the QMSR: these records, along with supplier audit reports, are no longer exempt from FDA inspection as they were under the prior QSR.
  • Training and personnel competence - ensuring personnel are qualified and trained for their quality system responsibilities

The Limitations of Manual Compliance Systems

  • Paper Trails and Siloed Documentation

    Manual processes rely on paper binders, spreadsheets, and disparate systems. This fragmentation makes it nearly impossible to maintain version control or ensure all staff are following the latest SOPs.

  • Audit Friction and Risk Exposure

    Without automation, audit preparation becomes time-consuming and error-prone. Missing records, undocumented changes, or inconsistent processes increase regulatory risk, potentially leading to warning letters, fines, or recalls.

What to Look for in FDA 21 CFR Part 820 Compliance Software

Automated Document Control & Versioning

Ensure all SOPs, quality manuals, and regulatory documents are controlled, updated, and versioned electronically.

Electronic Signatures & Time-Stamped Audit Trails

Meet Part 11 requirements with secure eSignatures and complete traceability of approvals and actions.

Lifecycle Traceability: Design to Complaints

Maintain end-to-end traceability from design inputs and verification through production, complaints, and CAPA.

Supplier, Change & Training Management

Streamline supplier audits, change management workflows, and employee training programs.

Validation Support & Cloud-Hosted Solutions

Choose platforms offering pre-validated environments and cloud scalability for reduced IT burden and global accessibility.

Product Risk Management

Look for software that embeds risk management directly into design and quality workflows, rather than treating it as a standalone activity, risk assessments should stay linked to the design elements, processes, and CAPAs they inform.

Nonconformance Management

The software should capture, triage, and resolve nonconforming products systematically, with a clear record of disposition decisions and their connection to any resulting corrective action.

Production and Process Validation

Choose a platform that supports documenting and executing process validation activities, so evidence that a manufacturing process consistently produces a conforming product is maintained as part of the quality record, not tracked separately.

Post-Market Quality

Software should extend traceability beyond production into post-market activity, connecting complaints, adverse event reporting, and field actions back to the design and manufacturing records they relate to.

Internal Audits

Look for built-in audit scheduling, findings tracking, and corrective action linkage, since internal audit records are now within scope for FDA inspection under the QMSR.

Management Review and Quality Objectives

The platform should support structured management review cycles and let the organization define, track, and report on quality objectives over time, another area FDA inspectors can now examine directly.

Key Capabilities in Modern Compliance Platforms

  • Features & Benefits: Centralized Document Control, CAPA automation, secure eSignatures, and audit readiness.
  • Module Alignment to 21 CFR Subparts (Table): Map software modules directly to Subparts A–O (e.g., Design Controls → Subpart C, CAPA → Subpart J).
  • Regulatory Updates & QMSR Readiness: Future-proof compliance with alignment to FDA’s new Quality Management System Regulation (QMSR).
  • Compliance Templates: Pre-built templates for Part 820, Part 11, ISO 14971 (risk management), and ISO 13485.
  • Analytics, Traceability, Cost & Time Savings: AI dashboards help identify risks, track compliance metrics, and reduce the cost of audits.
  • AI-Driven Validation and Integrated QMS Modules: Accelerate software validation and integrate QMS modules for seamless workflows.
  • ERP/MRP/LIMS Integrations: Connect compliance processes with ERP, manufacturing, and lab systems for full operational visibility.
Key Capabilities in Modern Compliance Platforms

What Changed When the FDA QMSR Took Effect in 2026?

The QMSR replaced the former QSR on February 2, 2026, marking the most significant change to FDA's device quality regulation in decades. The new framework brings stronger alignment with ISO 13485:2016, a greater emphasis on risk-based decision-making, and a revised FDA inspection approach built specifically around the QMSR rather than the prior Quality System Inspection Technique (QSIT).

Area Former QSR Current QMSR
Official name Quality System Regulation Quality Management System Regulation
Structure Detailed Subparts A–O Streamlined Part 820 with ISO 13485:2016 incorporated by reference
Inspection approach QSIT FDA Compliance Program 7382.850
Risk management Requirements distributed across different sections Greater emphasis on risk management and risk-based decisions
Internal quality records Certain reports were previously exempt from inspection Management-review, supplier-audit and quality-audit records may be reviewed
ISO 13485 relationship Similar but separate ISO 13485:2016 incorporated by reference

Choosing the Right Software: Buyer-centric Criteria

Selecting an FDA 21 CFR Part 820 compliance solution requires more than just ticking boxes—the right fda 21 cfr part 820 compliance software for medical devices must align with your processes, scale with your growth, and support long-term regulatory readiness. Key buyer-centric criteria include:

Feature Completeness and Traceability

A strong compliance solution should map directly to the requirements of FDA 21 CFR Part 820, covering design controls, document management, CAPA, training, and supplier oversight. Look for complete traceability from product design inputs to post-market surveillance, ensuring a closed-loop quality system.

Usability and User Adoption

Even the most feature-rich platform can fail if it isn’t easy to use. An intuitive interface with role-based dashboards, mobile access, and guided workflows increases user adoption across engineering, quality, and regulatory teams. Vendors should also provide comprehensive onboarding and training to accelerate adoption.

Validation Documentation & Audit Readiness

Compliance software must be validated for its intended use. Seek vendors that provide validation templates, documentation packages, and continuous update support. Audit-ready reporting, electronic signatures, and built-in audit trails reduce inspection stress and regulatory risk.

Integration Ecosystem and Vendor Support

Your compliance platform should integrate seamlessly with ERP, MES, LIMS, and other enterprise systems to avoid silos. Beyond technology, evaluate the vendor’s support model: Do they provide regulatory guidance? Do they update their solution to align with FDA and ISO changes? Vendor partnership is as important as the product.

ROI: Cost, Time-to-Market, Risk Reduction

The right software should deliver measurable business outcomes. Evaluate whether the platform helps reduce rework, accelerate product launches, improve compliance outcomes, and lower the cost of quality. ROI should be framed not just in financial savings but also in reduced risk exposure and faster market entry.

How Do You Implement 21 CFR Part 820 Software?

conduct an effective management audit
  • Complete a QMSR gap assessment. Evaluate current quality processes, documentation, and records against QMSR requirements to identify where existing practices fall short of the new framework.
  • Define the software's intended use. Establish exactly what the platform needs to do, which processes, record types, and regulatory requirements it must support, before configuration begins.
  • Map current and future workflows. Document how quality processes work today and how they should work once digitized, so the software configuration reflects an improved process rather than replicating existing inefficiencies.
  • Create a risk-based assurance plan. Prioritize implementation and validation effort according to the risk each process or record type carries, focusing the most rigorous scrutiny where failure would have the greatest consequence.
  • Configure and pilot priority processes. Begin with the highest-priority workflows identified in the gap assessment, testing configuration in a controlled pilot before expanding further.
  • Migrate and verify records. Transfer existing quality records into the new system and verify their accuracy and completeness against the source records before relying on them.
  • Train users and monitor effectiveness. Train all relevant personnel on their role-specific workflows, then continue monitoring adoption and system performance after go-live to confirm the implementation is delivering the intended compliance and efficiency outcomes.
how CQ helps companies with electronic medical device reporting

How Does 21 CFR Part 820 Software Benefit Medical Device Manufacturers?

The value of 21 CFR Part 820 compliance software becomes clearest when you trace it as a connected chain, from the regulation itself through to measurable business results:

Regulatory requirements → controlled quality processes → automated workflows → traceable records → inspection readiness → measurable business benefits

  • Regulatory requirements set the baseline: the QMSR defines what manufacturers must demonstrate about their design, production, and quality processes.
  • Controlled quality processes translate those requirements into defined, repeatable procedures, the organization's actual quality system, not just its documentation.
  • Automated workflows take those controlled processes and remove the manual effort of routing, tracking, and escalating quality events, so the process runs consistently regardless of who's involved.
  • Traceable records are the natural byproduct of automated workflows, every action taken generates a timestamped, attributable record without extra effort from the team.
  • Inspection readiness follows directly from traceable records: when documentation is current and connected by default, preparing for an FDA inspection becomes a matter of retrieval, not reconstruction.
  • Measurable business benefits are what inspection readiness ultimately makes possible, reduced audit preparation time, fewer compliance findings, faster corrective action closure, and quality data reliable enough to inform real business decisions.

Buyer’s Checklist & Quick Comparison

To simplify evaluation, medical device manufacturers should use a buyer’s checklist to compare FDA 21 CFR Part 820 compliance solutions. This structured approach helps align software capabilities with business and compliance needs.

21 CFR Part 820 Software Evaluation Criteria

An effective comparison should cover:

  • Quality Planning

    Core Features

    Document control, CAPA, design control, complaint handling, training, supplier management.

  • Design Control

    Part 11 Support

    eSignatures, time-stamped audit trails.

  • Material and Component Inspection

    Validation Packages

    Availability of vendor-provided IQ/OQ/PQ documentation.

  • Manufacturing Process Control

    Scalability & Deployment

    Cloud-hosted vs. on-premise options.

  • Product Testing

    Integrations

    ERP, MES, LIMS, CRM.

  • Calibration and Maintenance

    Support & Services

    Training, regulatory guidance, implementation support.

Conclusion & Next Steps

  • Compliance with FDA 21 CFR Part 820 is non-negotiable for medical device manufacturers. From design controls and supplier management to CAPA and complaint handling, every element of the Quality System Regulation must be documented, traceable, and audit-ready. Relying on manual systems or disconnected tools creates unnecessary risks—delays, errors, warning letters, or even product recalls.
  • Modern FDA 21 CFR Part 820 compliance software provides a centralized, automated, and validated environment to manage all quality processes. Beyond reducing compliance risk, it empowers teams to accelerate product development, improve collaboration, and ensure consistent delivery of safe, effective medical devices to market.
  • The next step for manufacturers is to see compliance software in action. Requesting a demo allows you to evaluate features firsthand, understand how modules align with FDA subparts, and assess usability for your teams. Many organizations also begin with a pilot program to validate ROI, test integrations, and measure adoption before scaling enterprise-wide. Consulting with experts ensures your compliance strategy aligns with both current FDA requirements and upcoming QMSR updates.
  • To support your decision-making, explore ComplianceQuest’s library of educational resources. From whitepapers on FDA 21 CFR Part 820 compliance to on-demand webinars with regulatory experts and guides on QMSR readiness, these materials provide deeper insights into building a strong compliance foundation. Leveraging these resources can help your team stay informed, reduce risk, and prepare for a smooth transition to modern compliance practices.

Choose ComplianceQuest’s FDA 21 CFR Part 820 Compliance Software for Medical Devices—trusted by industry leaders—to streamline your compliance processes, simplify documentation, and empower your team to maintain quality, efficiency, and regulatory adherence across your organization.


Request a Personalized Demo

Frequently Asked Questions

  • Under the current QMSR, 21 CFR Part 820 incorporates ISO 13485:2016 by reference for most quality system requirements, so the two are no longer separate, parallel standards, ISO 13485 now forms the substantive core of Part 820 itself. FDA retains a smaller set of FDA-specific requirements alongside ISO 13485, covering areas like Medical Device Reporting, UDI, and inspection authority over certain quality records.

  • Yes. The QMSR itself represents exactly that kind of change, replacing the former QSR in February 2026, and FDA continues to issue updated guidance interpreting how the regulation applies to specific submission types and device categories. Manufacturers should expect the regulatory interpretation to keep evolving even though the core regulatory text is now more stable than under the prior subpart structure.

  • ComplianceQuest connects the quality workflows the QMSR covers document control, CAPA, design controls, supplier management, training, and audits into a single system, so records stay traceable and current by default rather than requiring separate reconciliation. That connected structure is what allows manufacturers to stay inspection-ready continuously, not just ahead of a scheduled audit.

  • Digital tracking works best when quality objectives are defined within the same system that runs day-to-day quality processes, so progress against each objective is measured directly from live process data rather than manually compiled. Dashboards and reporting tied to management review cycles let manufacturers monitor objective progress continuously and surface gaps before a scheduled review.

  • An LMS supporting Part 820 compliance should tie training assignments directly to job roles and document revisions, automatically reassigning training when a controlled procedure changes. Certification tracking, automated reminders, and a complete, audit-ready training record for every employee are equally essential for demonstrating personnel competence during an inspection.

  • The best fit depends on an organization's existing systems, scale, and specific compliance gaps, but the software should, at minimum, offer end-to-end traceability, automated audit trails, and connected quality workflows so evidence can be retrieved on demand rather than assembled under pressure. Evaluating vendors against the criteria such as feature completeness, validation support, integration ecosystem, and vendor support is the most reliable way to determine the right fit for a specific organization.

  • Yes. Design controls are a core requirement retained under the QMSR, and compliance software should support the full design control lifecycle, from design inputs and outputs through verification, validation, and design history file documentation. Connecting design controls to downstream processes like risk management and CAPA is what allows a design-related issue discovered later in the product lifecycle to trace cleanly back to its origin.

Related Articles

  • 21 CFR Part 11 Guidelines for Pharmaceuticals: A Complete Compliance Guide

    Read More
  • The Merger of ISO 13485 and FDA QSR 21 CFR 820 for Medical Devices – Proposed Changes and Implications

    Read More
×
spinner
Consult Now

Comments